Altimmune, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 910 CLOPPER ROAD, GAITHERSBURG, MD, 20878
Mailing Address 910 CLOPPER ROAD, GAITHERSBURG, MD, 20878
Phone 2406541450
Fiscal Year End 1231
EIN 202726770
Financial Overview
FY2025
$224.89M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 10-K Annual financial report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
Annual Reports
10-K March 6, 2026
- Successfully completed Phase 2b MOMENTUM trial for Pemvidutide in obesity, demonstrating statistically significant weight loss and a favorable safety profile.
- Secured $150 million in non-dilutive financing, significantly bolstering cash reserves without shareholder dilution.
Insider Trading
BUY 6 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.